Y S Chun1, J N Vauthey. 1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Unit 444, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract
AIM: To review the advances in the past decade that have enabled more patients with colorectal liver metastases (CRLM) to undergo curative hepatic resection. METHODS: A comprehensive literature review and pertinent data published on advanced CRLM from The University of Texas M. D. Anderson Cancer Center were used for this review. RESULTS: Criteria for resectability of CRLM have expanded with the advent of effective chemotherapy, improved surgical technique, and novel strategies such as preoperative volumetry, portal vein embolization, and two-stage hepatectomy. Despite the aggressiveness of these approaches to treating patients with advanced disease, recent series show an improvement in 5-year survival rate for patients with CRLM. CONCLUSIONS: Advances in multidisciplinary management and careful patient selection have enabled more patients to undergo curative resection for CRLM, with corresponding improvement in survival rates.
AIM: To review the advances in the past decade that have enabled more patients with colorectal liver metastases (CRLM) to undergo curative hepatic resection. METHODS: A comprehensive literature review and pertinent data published on advanced CRLM from The University of Texas M. D. Anderson Cancer Center were used for this review. RESULTS: Criteria for resectability of CRLM have expanded with the advent of effective chemotherapy, improved surgical technique, and novel strategies such as preoperative volumetry, portal vein embolization, and two-stage hepatectomy. Despite the aggressiveness of these approaches to treating patients with advanced disease, recent series show an improvement in 5-year survival rate for patients with CRLM. CONCLUSIONS: Advances in multidisciplinary management and careful patient selection have enabled more patients to undergo curative resection for CRLM, with corresponding improvement in survival rates.
Authors: Jussuf T Kaifi; Miriam Kunkel; David T Dicker; Jamal Joude; Joshua E Allen; Avisnata Das; Junjia Zhu; Zhaohai Yang; Nabeel E Sarwani; Guangfu Li; Kevin F Staveley-O'Carroll; Wafik S El-Deiry Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Cathal O'Leary; Megan Greally; John McCaffrey; Peter Hughes; Leo L P Lawler; Martin O'Connell; Tony Geoghegan; Cormac Farrelly Journal: Ir J Med Sci Date: 2018-03-06 Impact factor: 1.568
Authors: Sean Maroney; Carlos Chavez de Paz; Mark E Reeves; Carlos Garberoglio; Elizabeth Raskin; Maheswari Senthil; Jukes P Namm; Naveenraj Solomon Journal: J Gastrointest Surg Date: 2017-11-09 Impact factor: 3.452
Authors: Alan A Thomay; David M Nagorney; Steven J Cohen; Elin R Sigurdson; Mark J Truty; Barbara Burtness; Michael J Hall; Yun Shin Chun Journal: J Gastrointest Surg Date: 2013-09-04 Impact factor: 3.452
Authors: Jussuf T Kaifi; Miriam Kunkel; Junjia Zhu; David T Dicker; Niraj Gusani; Zhaohai Yang; Nabeel E Sarwani; Guangfu Li; Eric T Kimchi; Kevin F Staveley-O'Carroll; Wafik S El-Deiry Journal: Cancer Biol Ther Date: 2013-10-23 Impact factor: 4.742